Related Experiment Video
Updated: Feb 5, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: a retrospective, cross-sectional
Theresa R Tonozzi1, Glenn D Braunstein1, Anja Kammesheidt1
1Pathway Genomics, San Diego, CA 92121, USA.
Aim:
To compare pharmacogenetic test predictions with self-reported treatment experience and side effect tolerability among patients with depression taking psychotherapeutic medications.
Methods:
Subjects completed a survey recalling medication effectiveness and side effects and then underwent pharmacogenetic testing.
Results:
Our 15 gene pharmacogenetic panel predicted efficacy (p < 0.001) but did not predict side effect tolerability (p = 0.70) in a group of 352 patients. The pharmacogenetic panel and reported efficacy corresponded 60% of the time and medication tolerability agreed 71% of the time.
Conclusion:
Pharmacogenetic testing may be a useful adjunct to predict efficacy of medications used to treat depression.
Related Concept Videos
Profile Leveling and Cross Sections
Cross-Sectional Research
Bipolar Disorder
Depressive Disorders: Etiology
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Depressive Disorders: MDD and Dysthymia
Finding Volume Using Cross-Sectional Area

